Johnson & Johnson Ordered to Pay Billion-Dollar Penalty for Risperdal
Friday, April 13, 2012
Johnson & Johnson must pay a $1.1 billion judgment after an Arkansas jury found the company guilty of misleading doctors and patients about the antipsychotic drug Risperdal.
The company was accused of defrauding Medicaid by not properly disclosing Risperdal’s risks and deceptively marketing it as safer and more effective than similar medicines. Johnson & Johnson also marketed the drug towards children and seniors with various problems, doing so without the approval of the Food and Drug Administration and, indeed, after being warned not to do so. The FDA approved Risperdal only for treatment of schizophrenia, bipolar disorder, and irritability associated with autistic disorder in children and adolescents. Doctors, however, can prescribe it for other conditions, which they were encouraged to do by misleading sales letters from Johnson & Johnson.
The penalty is the third and largest so far handed down by a state justice system against the company for the way it sold Risperdal. Previous penalties were issued in Louisiana and South Carolina and the company settled with Texas in January. So far 11 states have sued J&J over Risperdal violations.
At its peak in 2007, the drug made $4.5 billion in sales for Johnson & Johnson. The company’s net income last year was $9.7 billion based on $65 billion of revenue. Because no criminal charges have been filed against company executives, it would not be surprising if J&J and other pharmaceutical continued to pursue similar deceptive practices, factoring possible fines, penalties and legal fees into their financial plans.
-David Wallechinsky, Noel Brinkerhoff
To Learn More:
J&J Must Pay $1.1 Billion Penalty in Arkansas Risperdal Case (by Eric Francis, Jef Feeley and David Voreacos, Bloomberg)
Arkansas Judge Fines J&J $1.1B in Risperdal Case (by Chuck Bartels, Associated Press)
VA Awards New Contract for Useless Drug (by David Wallechinsky, AllGov)
VA Spent $717 Million for Useless Post-Traumatic Stress Drug (by David Wallechinsky, AllGov)
- Top Stories
- Unusual News
- Where is the Money Going?
- U.S. and the World
- Appointments and Resignations
- Latest News
- Your Tax Dollars at Work…State Dept. Lobbies Abroad for Monsanto Biotech Seeds
- Director of the Federal Housing Finance Agency: Who Is Mel Watt?
- Pacific Islanders Ask U.S. Military to not Use Pagan Island for Target Practice
- Wrongful Death Lawsuit against Wells Fargo in Wrongful Foreclosure Case
- Ambassador from Chad: Who Is Maitine Djoumbe?